脑心通联合文拉法辛治疗脑卒中后抑郁的临床研究  

Clinical Study of Naoxintong Plus Venlafaxine in the Treatment of Post-stroke Depression

作　　者：韩英姬[1] HAN Yingji(Department of Neurology,Yanbian Brain Hospital,Yanji Jilin 133000,China)

机构地区：[1]延边脑科医院神经内科,吉林延吉133000

出　　处：《中国卫生标准管理》2021年第20期75-78,共4页China Health Standard Management

摘　　要：目的探究脑心通+文拉法辛治疗脑卒中后抑郁的临床应用价值。方法选取我院2018年4月—2019年12月脑卒中后抑郁患者82例,按随机数字表法分为对照组和观察组两组,每组41例,对照组采用文拉法辛治疗,观察组采用脑心通+文拉法辛治疗。对两组相关数据进行比较。结果观察组汉密尔顿抑郁量表(HAMD)评分、国家健康研究所卒中量表(NIHSS)评分低于对照组,差异有统计学意义(P<0.05);观察组5-羟色胺(5-HT)、去甲肾上腺素(NE)水平高于对照组,差异有统计学意义(P<0.05)。结论对该疾病患者实施此治疗方式具有良好效果。Objective To explore the clinical value of Naoxintong+venlafaxine in the treatment of post-stroke depression.Methods A total of 82 patients with post-stroke depression from April 2018 to December 2019 were selected,and all them were divided into control group(41 cases)and observation group(41 cases)according to random number table.The control group received venlafaxine treatment,the observation group received Naoxintong plus venlafaxine.Finally,the relevant data of two groups were compared.Results The scores of Hamilton depression scale(HAMD)and national institutes of health stroke scale(NIHSS)in the observation group were lower than those in the control group,with statistically significant differences(P<0.05).The level of 5-hydroxytryptamine(5-HT)and norepinephrine(NE)in the observation group were higher than those in the control group,with statistically significant differences(P<0.05).Conclusion It has a good effect to apply this therapy to the patients with this disease.

关 键 词：脑心通 文拉法辛 脑卒中 抑郁 5-羟色胺 甲肾上腺素 

分 类 号：R743.3[医药卫生—神经病学与精神病学]